Irinotecan (Camptosar) in Patients With Advanced Sarcomas
Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
Primary Objectives:
1. To determine the efficacy of the topoisomerase I (topo I) inhibitor irinotecan,
delivered via a low-dose protracted schedule to patients with advanced sarcoma.
2. To determine the toxicity profile of irinotecan, using a protracted schedule, in this
pretreated patient population.